Mannkind, Game-Chancer in Sachen Diabetik? (Seite 406)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 10.05.24 08:11:18 von
neuester Beitrag 10.05.24 08:11:18 von
Beiträge: 6.836
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 7
Gesamt: 594.318
Gesamt: 594.318
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: NNFN
4,0150
EUR
-0,42 %
-0,0170 EUR
Letzter Kurs 10.05.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,2570 | +96,67 | |
| 17,440 | +44,61 | |
| 1,9750 | +27,42 | |
| 1,8400 | +26,03 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7275 | -18,72 | |
| 0,7100 | -19,32 | |
| 0,5350 | -20,15 | |
| 3,0800 | -23,76 | |
| 3,0740 | -77,41 |
Beitrag zu dieser Diskussion schreiben
Feedback
Man kann von dem Feuerstein ja halten was man will, aber das frag ich mich auch schon die ganze Zeit, warum da nichts kommt und MNKD könnte wirklich jetzt eine sehr dünne Kapitaldecke/Cashposition haben...
MannKind Silent on Debt Conversion, Suggesting Costly Cash Settlement
VALENCIA, Calif. (TheStreet) -- The deadline for MannKind (MNKD) to settle debt totaling $32 million passed five days ago. The company has said nothing publicly, which probably means debt holders were repaid with cash.
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
It's possible, but unlikely, that MannKind convinced some of its debt holders to accept company stock.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks with serious upside potential in the next 12-months. Learn more.
MannKind CFO Matt Pfeffer didn't respond to e-mailed questions about the outcome of the debt settlement issue, but company executives may have something to say about the matter when they speak at an investor conference on Thursday.
Must Read: Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices
Poor sales of Mannkind's inhaled mealtime insulin Afrezza, as reported by marketing partner Sanofi (SNY - Get Report) , have taken a big bite out of Valencia, Calif-based MannKind's stock price, making it difficult for the company to reach agreement with holders of $100 million in convertible debt that was due on August 15.
Of the original $100 million in debt, $28 million was rolled over into new convertible debt due in 2018 and $8 million was converted into MannKind stock, MannKind said in August.
To settle the remaining $64 million in debt, MannKind floated a proposal to exchange half, or $32 million, for company stock and use $32 million in cash to repay the balance. The deadline for the stock-for-debt offer expired on Sept. 30.
Negotiations between MannKind and the remaining debt holders reached an impasse, according to a source familiar with the situation. If MannKind was unable to convert any of the $32 million in outstanding August 2015 debt into stock, the company would have been forced to double the cash -- $64 million -- necessary to make the debt issue go away. (MannKind would have been compelled to announce an extension of the stock-for-debt offer, so the company's silence means it was settled.)
The problem for MannKind is that it can't really afford to spend cash to settle old debts. The company had $107 million in cash on hand as of June 30, of which $25 million is restricted and cannot be touched due to other outstanding debt obligations.
Subtract another $64 million to satisfy current debt holders reduces MannKind's cash balance to $18 million.
http://www.thestreet.com/story/13312326/1/mannkind-silent-on…
MannKind Silent on Debt Conversion, Suggesting Costly Cash Settlement
VALENCIA, Calif. (TheStreet) -- The deadline for MannKind (MNKD) to settle debt totaling $32 million passed five days ago. The company has said nothing publicly, which probably means debt holders were repaid with cash.
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
It's possible, but unlikely, that MannKind convinced some of its debt holders to accept company stock.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks with serious upside potential in the next 12-months. Learn more.
MannKind CFO Matt Pfeffer didn't respond to e-mailed questions about the outcome of the debt settlement issue, but company executives may have something to say about the matter when they speak at an investor conference on Thursday.
Must Read: Morgan Stanley Says These 9 Health Care Stocks Are Best-Positioned, Despite Rising Drug Prices
Poor sales of Mannkind's inhaled mealtime insulin Afrezza, as reported by marketing partner Sanofi (SNY - Get Report) , have taken a big bite out of Valencia, Calif-based MannKind's stock price, making it difficult for the company to reach agreement with holders of $100 million in convertible debt that was due on August 15.
Of the original $100 million in debt, $28 million was rolled over into new convertible debt due in 2018 and $8 million was converted into MannKind stock, MannKind said in August.
To settle the remaining $64 million in debt, MannKind floated a proposal to exchange half, or $32 million, for company stock and use $32 million in cash to repay the balance. The deadline for the stock-for-debt offer expired on Sept. 30.
Negotiations between MannKind and the remaining debt holders reached an impasse, according to a source familiar with the situation. If MannKind was unable to convert any of the $32 million in outstanding August 2015 debt into stock, the company would have been forced to double the cash -- $64 million -- necessary to make the debt issue go away. (MannKind would have been compelled to announce an extension of the stock-for-debt offer, so the company's silence means it was settled.)
The problem for MannKind is that it can't really afford to spend cash to settle old debts. The company had $107 million in cash on hand as of June 30, of which $25 million is restricted and cannot be touched due to other outstanding debt obligations.
Subtract another $64 million to satisfy current debt holders reduces MannKind's cash balance to $18 million.
http://www.thestreet.com/story/13312326/1/mannkind-silent-on…
Kauft statt kaut!
Antwort auf Beitrag Nr.: 50.769.531 von Gangal am 04.10.15 09:11:27Oder wie seht Ihr denn das?
Übergabe der klinischen Studie an Health Authority Germany: Ethics Commission
Übergabe der klinischen Studie an Health Authority Germany: Ethics Commission
Tolle Seite, müßte doch mit dem Teuel zugehen wenn sich solch eine revolutionäre einfache und schmerzfreie Therpie nicht durchsetzen würde!
Trading Spotlight
Wäre schön wenn es so kommt...
I spoke to 1 endo(sorry no name/privacy issues)told me that Afrezza is incredible in lowering A1C levels and it will be a blockbuster
Aus dem Yahoo Board (kann ich keinen Link schicken)
I spoke to 1 endo(sorry no name/privacy issues)told me that Afrezza is incredible in lowering A1C levels and it will be a blockbuster
Aus dem Yahoo Board (kann ich keinen Link schicken)
Interessant... Kommt es bald zur Zulassung in Deutschland bzw. Europa???
On the clamp study that was just completed, look at the health authorities reviewing:Germany & USA!!!
https://clinicaltrials.gov/archive/NCT02470637/2015_09_29
On the clamp study that was just completed, look at the health authorities reviewing:Germany & USA!!!
https://clinicaltrials.gov/archive/NCT02470637/2015_09_29
Quelle investor village von techstockguru gepostet heute
The explanation is really easy and its 100% factual. SNY has said all along that they would go thru a process of education, target certain endos and early adopters, work thru insurance approvals, start print ads, seek better labeling thru further trials and then roll out on a large scale. We are just starting the 2nd half of the game and are right on track for a victory. Scrip counts will eventually hockey stick once all the steps are in place and execution has been given enough time.
DYOR.LINK NICHT POSTBAR
The explanation is really easy and its 100% factual. SNY has said all along that they would go thru a process of education, target certain endos and early adopters, work thru insurance approvals, start print ads, seek better labeling thru further trials and then roll out on a large scale. We are just starting the 2nd half of the game and are right on track for a victory. Scrip counts will eventually hockey stick once all the steps are in place and execution has been given enough time.
DYOR.LINK NICHT POSTBAR
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
